Myriad Genetics, Inc. MYGN recently launched the Myriad Collaborative Research Registry (MCRR), a comprehensive pan-cancer research platform designed to advance patient care. MCRR, formerly known as the Precision Therapeutics Registry, contains new data on germline and tumor test results for the company’s cancer products in more than 1 million patients.
With the latest enhancements, MCRR is one of the largest pan-cancer registries currently free for research use. It also supports the transparent sharing of clinical data to advance the field.
The meaning of MCRR
MCRR is built on DNAnexus, the leading enterprise Precision Health platform, providing a secure and easy-to-use interface for scientific data analysis, collaboration, and discovery. With Institutional Review Board approval, the registry expands access to Myriad Genetics’ extensive repository of linked genomic and clinical data to allow researchers to discover deeper insights and accelerate the pace of precision cancer research to better prevent, detect and treat disease.
Image source: Zacks Investment Research
MCRR currently contains de-identified research data for a wide range of cancer indications and includes genomic testing data related to family history, ethnicity, and clinical characteristics. This multi-omics resource combines disparate molecular information, including germline variation, RNA-based gene expression classifiers, homologous recombination defect assessment, tumor variation, microsatellite instability, tumor mutation burden, and PD-L1 status. Together they provide a holistic view of advanced insights.
Over time, this registry will continue to expand to include patient outcomes, treatment response, and other tools to enhance the types of studies that can be conducted.
more news
The scale and scope of MCRR underscores Myriad Genetics’ continued commitment to being a partner throughout the health data ecosystem. Building on its open data sharing efforts, the registry shares real-world data in a secure and interactive group browser.
According to a MYGN spokesperson, the purpose of the registration is to put this extensive data set into the hands of interested researchers, allowing them to easily access and evaluate the data, run their own queries and test hypotheses to advance the understanding of cancer. Understand, thereby promoting patient care.
Industry prospects
According to a report by Precedence Research, the global cancer treatment market will be worth US$164 billion in 2022 and is expected to grow at a compound annual growth rate of 9.2% by 2032.
Other noteworthy developments
The company provides genetic tests that help assess the likelihood of a disease or its progression and guide treatment decisions across medical specialties, with the goal of significantly improving patient care and reducing healthcare costs. One of its key focus areas is oncology, where the company has specialized products, capabilities and expertise.
Earlier in October 2023, MYGN and renowned Sample to Insight solution provider QIAGEN announced a master collaboration agreement to develop companion diagnostic tests in the cancer field. The alliance between QIAGEN and Myriad Genetics brings together the best of each company. The partnership aims to provide pharmaceutical companies with innovative services and products, facilitate the development and commercialization of proprietary cancer tests for the U.S. clinical market, and provide distributable companion diagnostic test kits for global markets.
Cost-effectiveness
Myriad Genetics shares have fallen 11.9% over the past six months, compared with the industry’s decline of 9%.
Zacks Rank and Key Picks
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
Within the broader healthcare sector, some of the better-ranked stocks are hematology HAE, isulet PODD and Dexcon DXCM. Haemonetics and DexCom both currently carry a Zacks Rank #2 (Buy), and Insulet carries a Zacks Rank #1 (Strong Buy).you can see The complete list of today’s Zacks #1 Rank stocks is here.
Haemonetics stock has gained 8.2% in the last year. Over the past 30 days, Haemonetics’ profit forecast has increased from $3.86 in 2023 to $3.89, and its 2024 profit forecast has increased from $4.11 to $4.15.
HAE’s earnings have exceeded expectations in each of the past four quarters, with an average surprise of 16.1%. In its last reported quarter, the company’s earnings unexpectedly rose 5.3%.
Over the past 30 days, Insulets’ 2023 earnings per share estimate has been revised upward from $1.90 to $1.91. The company’s shares fell 30.1% last year, compared with the industry’s decline of 1.6%.
PODD’s earnings have topped estimates in each of the last four quarters, with the average surprise rate being 105.1%. In the last reported quarter, the company delivered an average earnings surprise of 77.4%.
Over the past 30 days, DexComs’ 2023 earnings per share estimate has increased from $1.43 to $1.44. The company’s shares have gained 2.7% in the past year, compared with the industry’s gain of 4.1%.
DXCM has beaten earnings estimates in each of the past four quarters, with an average surprise rate of 36.4%. In the last reported quarter, the company delivered an average earnings surprise of 47.1%.
Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days.Click to get this free report
Haemonetics Corporation (HAE): Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Insulet Corporation (PODD): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
#Myriad #Genetics #MYGN #advances #platform #cancer #treatment
Image Source : finance.yahoo.com